Controlled-Release Peptide Microspheres for Sustained C5a Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic peptides and proteins have short plasma half-lives, requiring frequent injections to maintain therapeutic concentrations, and there is a need for controlled-release formulations to treat infections and diseases, including those caused by antibiotic-resistant bacteria and biofilms, while also inducing an immune response and targeting specific cells.
Innovation Solution
Development of controlled-release formulations using biodegradable microspheres to encapsulate C-terminal C5a analogs, which provide sustained release and target antigen-presenting cells, thereby activating the innate immune system and delivering therapeutic compounds effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic peptides or proteins are administered systemically to maintain therapeutic concentrations, then beneficial therapeutic effect is achieved, but frequent injections are required due to short plasma half-life
Solution Approach 1:
The therapeutic peptide or protein is encapsulated within biodegradable micro- or nanoparticles, creating a nested structure where the active agent is protected inside a carrier matrix. This nesting enables controlled release over extended periods, maintaining therapeutic concentrations without frequent dosing.
Solution Approach 2:
The controlled-release formulation is designed to release the therapeutic agent in advance and maintain therapeutic levels proactively over time. The micro- or nanoparticles are engineered to provide sustained release kinetics, ensuring therapeutic concentrations are maintained before the next dose is administered.
2Loss of time
If controlled-release formulations are used to extend duration of action, then frequency of injections is reduced, but formulation complexity increases
Solution Approach 1:
The release kinetics of the therapeutic agent are controlled by changing physical and chemical parameters of the micro- or nanoparticle matrix, such as polymer composition, crosslinking density, and particle size. These parameter adjustments enable tailored release profiles without requiring complex mechanical or electronic control systems.
3Reliability
If C5a analogs are used to activate and recruit neutrophils, then immune response is enhanced, but proinflammatory activities may cause harmful effects
Solution Approach 1:
The C5a analog is delivered through controlled-release formulations that concentrate the immune-stimulating effect at the site of infection or inflammation. This localized delivery enhances immune recruitment where needed while minimizing systemic proinflammatory effects and associated harmful side effects.
Data Source
AI summary
Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.